TEST

July 12, 2021

FluroTest Announces Pre-Emergency Use Authorization Filing with FDA; Provides Executive Update on Program Progress

FluroTech LTD. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary FluroTest Diagnostic Systems ("FluroTest" or The Company), a diagnostics technology leader in high output rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, today announced it has filed…...
Read More
June 17, 2021

FluroTest Diagnostic Systems Featured in Grand View Research Report Exploring Growth of COVID-19 Saliva Screening Test Potential Market

FluroTech LTD. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary FluroTest Diagnostics Systems ("FluroTest" or The Company), a diagnostics technology leader in high output rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, are pleased to be recognized…...
Read More
May 13, 2021

FluroTest and SNC-Lavalin Sign MoU to Bring Saliva Sample-Based SARS-CoV-2 Testing Solution System to Market in Canada and Beyond

FluroTech LTD. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary FluroTest Diagnostics Systems ("FluroTest" or The Company), a diagnostics technology leader in high output rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, today announces it has signed…...
Read More
May 10, 2021

FluroTest Provides Clinical Trial Update for High Volume COVID-19 Rapid Antigen Testing System

CALGARY, AB,, /PRNewswire/ - FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary FluroTest Diagnostics Systems ("FluroTest" or The Company), a diagnostics technology leader in high output rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, today…...
Read More
May 4, 2021

FLUROTEST PREPARES TO DETECT SARS-CoV-2 VARIANTS OF CONCERN WITH HIGH-THROUGHPUT COVID-19 TESTING PLATFORM

FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF), and subsidiary FluroTest Diagnostics Systems ("FluroTest" or The Company), a first-mover in surge-scale rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, are pleased to announce based on the data collected to…...
Read More
May 3, 2021

FluroTest Diagnostics Systems and Total Testing Solutions Sign Pilot Program MOU to Bring First High-Volume SARS-CoV-2 Testing System to California

FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) and subsidiary FluroTest Diagnostics Systems ("FluroTest" or The Company), a first-mover in surge-scale rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, today announces it has signed a strategic Memorandum of Understanding…...
Read More
April 13, 2021

FLUROTECH ANNOUNCES EARLY WARRANT EXERCISE INCENTIVE PROGRAM

FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) ("FluroTech" or the "Company"), a leading developer of spectroscopy-based technology, is pleased to announce it has received conditional approval from the TSX Venture Exchange (the "Exchange") to commence an Early Warrant Exercise Incentive Program…...
Read More
April 6, 2021

FORMER US ASSISTANT SECRETARY FOR HEALTH, ADMIRAL JOXEL GARCIA, MD, JOINS FLUROTEST ADVISORY BOARD TO SUPPORT COVID-19 RAPID ANTIGEN TESTING SYSTEM FOR THE MASSES

Calgary, Alberta, March 4, 2021 – FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF), and subsidiary FluroTest Diagnostics Systems ("FluroTest" or The Company), a first-mover in surge-scale rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, are pleased to announce…...
Read More
March 15, 2021

FLUROTECH AND FLUROTEST ANNOUNCE DEFINITIVE AMALGAMATION AGREEMENT

FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) (“FluroTech” or the “Company”), a leading developer of spectroscopy-based technology, and FluroTest Systems Ltd. (“FluroTest”), a first-mover in surge-scale rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, are pleased to announce…...
Read More
March 4, 2021

FLUROTECH PARTNERS WITH TOOLBOX MEDICAL INNOVATIONS FOR CLINICAL TRIAL OF MASS-SCALE COVID-19 TESTING PLATFORM

FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) (“FluroTech” or the “Company”), a leading developer of spectroscopy-based technology, together with joint venture FluroTest, LLC (“FluroTest”), a first-mover in surge-scale rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, are pleased…...
Read More